MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults

Blood

Volumn 129, Issue 1, 2017, Pages 114-125

  La Rosa, Corinna ^a   Longmate, Jeff ^a   Martinez, Joy ^a   Zhou, Qiao ^a   Kaltcheva, Teodora I ^a   Tsai, Weimin ^a   Drake, Jennifer ^a   Carroll, Mary ^a   Wussow, Felix ^a   Chiuppesi, Flavia ^a   Hardwick, Nicola ^a   Dadwal, Sanjeet ^a   Aldoss, Ibrahim ^a   Nakamura, Ryotaro ^a   Zaia, John A ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN IE1 EXON 4; CYTOMEGALOVIRUS ANTIGEN IE2 EXON5; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYMER; RECOMBINANT MODIFIED VACCINIA ANKARA; SMALLPOX VACCINE; TRIPLEX VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; IE1 PROTEIN, CYTOMEGALOVIRUS; IE2 PROTEIN, CYTOMEGALOVIRUS; IMMEDIATE EARLY PROTEIN; MATRIX PROTEIN; MVA VACCINE; PHOSPHOPROTEIN; TRANSACTIVATOR PROTEIN; VIRUS VACCINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL MEMBRANE; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HERPESVIRIDAE; HUMAN; HUMORAL IMMUNITY; HYPERBILIRUBINEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MYALGIA; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SKIN INDURATION; SKIN MANIFESTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS; VIREMIA; CLINICAL TRIAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; IMMEDIATE-EARLY PROTEINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; T-LYMPHOCYTES; TRANS-ACTIVATORS; VIRAL MATRIX PROTEINS; VIRAL VACCINES; YOUNG ADULT;

EID: 85014948810     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-07-729756     Document Type: Article

References (67)

1. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-e127.
2. Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3359-3364.
3. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427-2438.
4. Lacey SF, La Rosa C, Zhou W, et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis. 2006;194(10):1410-1421.
5. Gabanti E, Lilleri D, Ripamonti F, et al. Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection. Biol Blood Marrow Transplant. 2015;21(12):2192-2202.
6. Giménez E, Muñoz-Cobo B, Solano C, et al. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. Transpl Infect Dis. 2015;17(3):361-370.
7. Tormo N, Solano C, Benet I, et al. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46(11):1437-1443.
8. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74(4):211-220.
9. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290-299.
10. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113(25):6465-6476.
11. Ramanathan M, Tiera P, Battiwalla M, et al. Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: A CIBMTR analysis [abstract]. Blood. 2014;124(21):47a. Abstract 732.
12. Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016;3(2):e87-e98.
13. Wang Z, Zhou W, Srivastava T, et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology. 2008;377(2):379-390.
14. Gallez-Hawkins G, Thao L, Lacey SF, et al. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol Blood Marrow Transplant. 2005;11(11):890-902.
15. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects [published correction appears in J Exp Med. 2005;202(9):1301]. J Exp Med. 2005;202(5):673-685.
16. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. JExpMed. 2005;201(7):1031-1036.
17. Mayr A. [Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine] [in German]. Berl Munch Tierarztl Wochenschr. 1999;112(9):322-328.
18. Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B]. 1978;167(5-6):375-390.
19. Parrino J, McCurdy LH, Larkin BD, et al; VRC 201/203 Study Team. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine. 2007;25(8):1513-1525.
20. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010;201(9):1361-1370.
21. Seaman MS, Wilck MB, Baden LR, et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis. 2010;201(9):1353-1360.
22. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother. 2009;32(7):765-772.
23. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5(8):690-699.
24. Hardwick NR, Carroll M, Kaltcheva T, et al. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res. 2014;20(17):4459-4470.
25. Hui EP, Taylor GS, Jia H, et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013;73(6):1676-1688.
26. Cosma A, Nagaraj R, Bühler S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine. 2003;22(1):21-29.
27. Gudmundsdotter L, Nilsson C, Brave A, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27(33):4468-4474.
28. Gómez CE, Perdiguero B, García-Arriaza J, et al. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. PLoS One. 2015;10(11):e0141456.
29. Walsh SR, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013;207(12):1888-1897.
30. Wang Z, Martinez J, Zhou W, et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine. 2010;28(6):1547-1557.
31. Hanke T, McMichael AJ, Samuel RV, et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 2002;21(1-2):108-114.
32. Hanke T, McMichael AJ, Dennis MJ, et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine. 2005;23(12):1507-1514.
33. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant [published correction appears in J Infect Dis. 2013;208(6):1038]. J Infect Dis. 2012;205(8):1294-1304.
34. Kruszon-Moran D, Porter KS, McQuillan G, Billioux VG, Kim-Farley R, Hirsch R. Infectious disease prevalence in Los Angeles county - a comparison to national estimates, 1999-2004 birth rates for U.S. teenagers reach historic lows for all age and ethnic groups. NCHS Data Brief. 2012;(90):1-8.
35. Upfal MJ, Cinti S. Smallpox vaccination and adverse cardiac events. Emerg Infect Dis. 2004;10(5):961-962, discussion 962.
36. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A∗0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90(5):1751-1767.
37. Wölfl M, Kuball J, Eyrich M, Schlegel PG, Greenberg PD. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73(11):1043-1049.
38. La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transpl Int. 2011;24(9):920-931.
39. Wang Z, La Rosa C, Mekhoubad S, et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood. 2004;104(3):847-856.
40. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis. 2008;197(12):1634-1642.
41. Berencsi K, Gyulai Z, Gönczöl E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis. 2001;183(8):1171-1179.
42. Almanzar G, Schwaiger S, Jenewein B, et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. JVirol. 2005;79(6):3675-3683.
43. Jackson SE, Mason GM, Okecha G, Sissons JG, Wills MR. Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells. J Virol. 2014;88(18):10894-10908.
44. Lilleri D, Fornara C, Revello MG, Gerna G. Human cytomegalovirus-specific memory CD8+ and CD4+ T cell differentiation after primary infection. J Infect Dis. 2008;198(4):536-543.
45. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617.
46. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev. 2010;235(1):244-266.
47. Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43(3):276-282.
48. Cottingham MG, Carroll MW. Recombinant MVA vaccines: dispelling the myths. Vaccine. 2013;31(39):4247-4251.
49. Meyer J, Harris SA, Satti I, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013;31(7):1026-1033.
50. Elizaga ML, Vasan S, Marovich MA, et al; MVA Cardiac Safety Working Group. Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review. PLoS One. 2013;8(1):e54407.
51. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201-210.
52. Maecker HT, Hassler J, Payne JK, et al. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 2008;9:9.
53. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood. 2010;115(9):1678-1689.
54. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines. 2010;9(2):157-173.
55. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189-209.
56. Zhang X, Cassis-Ghavami F, Eller M, et al. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol. 2007;81(13):7022-7033.
57. Khan N, Best D, Bruton R, Nayak L, Rickinson AB, Moss PA. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol. 2007;178(7):4455-4465.
58. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113-5123.
59. Sukdolak C, Tischer S, Dieks D, et al. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant. 2013;19(10):1480-1492.
60. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.
61. Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7(285):285ra63.
62. Barrett AJ, Bollard CM. The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation. Ann Transl Med. 2015;3(5):62.
63. Kotton CN, Kumar D, Caliendo AM, et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333-360.
64. Marchini A, Liu H, Zhu H. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. JVirol. 2001;75(4):1870-1878.
65. Greaves RF, Mocarski ES. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J Virol. 1998;72(1):366-379.
66. Day EK, Carmichael AJ, ten Berge IJ, Waller EC, Sissons JG, Wills MR. Rapid CD8+ Tcell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J Immunol. 2007;179(5):3203-3213.
67. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med. 2003;9(9):1131-1137.